Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003114772 | SCV003785221 | uncertain significance | Walker-Warburg congenital muscular dystrophy | 2022-10-24 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 279 of the FKTN protein (p.Glu279Gly). This variant is present in population databases (rs760534318, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with FKTN-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FKTN protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003162136 | SCV003857380 | uncertain significance | Cardiovascular phenotype | 2022-12-11 | criteria provided, single submitter | clinical testing | The p.E279G variant (also known as c.836A>G), located in coding exon 6 of the FKTN gene, results from an A to G substitution at nucleotide position 836. The glutamic acid at codon 279 is replaced by glycine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |